What Is Retatrutide?
Retatrutide is an experimental peptide-based medication being developed by Eli Lilly.
It is often described as a:
Triple agonist
because it activates three different hormone receptors:
GIP + GLP-1 + glucagon
That makes it different from:
Semaglutide → primarily GLP-1
and:
Tirzepatide → GIP + GLP-1
Retatrutide adds a third target:
the glucagon receptor.
That extra pathway is one reason researchers believe retatrutide may have particularly powerful effects on:
appetite + food intake + glucose metabolism + energy expenditure + body weight.
As of September 2026, retatrutide remains investigational and is not approved by FDA or any other regulatory agency. Lilly has said it plans to submit a Biologics License Application to FDA in the first quarter of 2027.
Why Are Researchers So Interested in It?
Retatrutide has produced some of the largest average weight reductions yet reported in medication-based obesity trials.
The excitement started with a Phase 2 trial published in the New England Journal of Medicine.
At 48 weeks, average weight change was:
1 mg → -8.7%
4 mg → -17.1%
8 mg → -22.8%
12 mg → -24.2%
compared with:
placebo → -2.1%.
Those results were already unusually strong.
Then Phase 3 pushed the numbers even higher.
What Did Phase 3 Show?
The major obesity trial is called:
TRIUMPH-1
It included 2,339 adults with obesity or overweight plus a weight-related condition who did not have diabetes.
At 80 weeks, average weight loss was:
Retatrutide 4 mg → 19.0%
Retatrutide 9 mg → 25.9%
Retatrutide 12 mg → 28.3%
Placebo → 2.2%.
At the highest dose, that translated to an average loss of:
70.3 pounds.
Even more striking:
45.3% of participants receiving 12 mg lost at least 30% of their starting body weight.
And:
27.2% lost at least 35%.
Those are very large reductions for a pharmacologic obesity treatment.
Did People Keep Losing Weight After 80 Weeks?
A prespecified extension followed a subgroup of participants with a baseline BMI of at least 35.
At 104 weeks, participants continuing toward the highest tolerated retatrutide dose lost as much as:
30.3% of their starting body weight on average.
That represented about:
85 pounds.
So the Phase 3 data suggest weight loss may continue beyond the first year in some patients.
That does not mean every individual will lose 30%.
These are group averages from a clinical trial.
How Does Retatrutide Work?
Retatrutide essentially combines signals from three metabolic hormone systems.
GLP-1
GLP-1 signaling can:
- Reduce appetite
- Increase feelings of fullness
- Slow gastric emptying
- Increase glucose-dependent insulin secretion
- Reduce glucagon under some circumstances
This is the pathway targeted by medications such as semaglutide.
GIP
GIP stands for:
glucose-dependent insulinotropic polypeptide.
GIP also affects insulin secretion and has complex effects involving:
- Adipose tissue
- Energy balance
- Appetite
- Metabolic signaling
Tirzepatide combines GIP and GLP-1 receptor activity.
Glucagon
This is the unusual addition.
Glucagon is usually associated with raising blood glucose, because it tells the liver to release stored glucose.
So at first glance, activating glucagon while treating obesity or diabetes sounds backwards.
But glucagon signaling can also increase:
energy expenditure + fat metabolism + thermogenesis.
Retatrutide is designed to combine those potential energy-expenditure effects with the appetite and glucose-control effects of GLP-1 and GIP.
In simplified terms:
eat less + feel fuller + improve metabolic signaling + potentially expend more energy.
That’s the scientific logic behind the triple agonist.
Does Retatrutide Increase Metabolism?
Possibly—but this needs careful wording.
The glucagon component has generated substantial interest because glucagon signaling can increase energy expenditure in experimental models.
That raises the possibility that retatrutide isn’t working solely by suppressing appetite.
However, the amount of human weight loss attributable specifically to increased energy expenditure versus reduced food intake has not been fully defined.
So calling retatrutide a:
“metabolism booster”
is too simplistic.
Its effect comes from an integrated metabolic-hormone system.
Is Retatrutide Better Than Tirzepatide?
We cannot say that yet.
Retatrutide’s Phase 3 results are extremely impressive.
But there has not been a completed direct randomized head-to-head trial establishing that retatrutide is superior to tirzepatide.
Comparing numbers from separate studies is tempting—but unreliable.
Different trials can involve different:
- Participants
- Baseline weights
- Duration
- Lifestyle interventions
- Statistical methods
- Discontinuation rates
- Dose-escalation schedules
So:
Retatrutide appears extraordinarily effective.
But:
“Retatrutide beats tirzepatide” is not currently an established clinical conclusion.
Retatrutide vs. Semaglutide
Same issue.
Semaglutide primarily targets:
GLP-1.
Retatrutide targets:
GLP-1 + GIP + glucagon.
Retatrutide has produced larger average weight reductions than were observed in many semaglutide obesity trials.
But again, cross-trial comparisons don’t prove direct superiority.
A true head-to-head study would be needed.
What About Type 2 Diabetes?
Retatrutide is also being developed for people with type 2 diabetes.
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes received retatrutide for 80 weeks.
Average weight loss reached:
12.7% with 4 mg
19.1% with 9 mg
20.8% with 12 mg
compared with:
4.0% with placebo.
Average A1C reductions reached approximately 1.4% to 1.6%, versus 0.2% with placebo.
Those results are important because people with type 2 diabetes often lose less weight with incretin-based therapies than people without diabetes.
What About Blood Sugar?
The Phase 3 diabetes program confirms that retatrutide has meaningful glucose-lowering effects.
An additional trial called TRANSCEND-T2D-1 reported average A1C reductions of up to:
2.0 percentage points
at 40 weeks, along with average weight loss reaching 16.8%.
That makes glucose metabolism and type 2 diabetes major areas of retatrutide development.
But retatrutide is still investigational.
It is not currently an approved diabetes drug.
What About Insulin Resistance?
Because retatrutide affects:
GLP-1 + GIP + glucagon + body weight + glucose metabolism,
insulin resistance is naturally relevant to the research.
Substantial weight loss itself can improve insulin sensitivity.
However, retatrutide should not yet be described as an approved treatment for:
- Prediabetes
- Insulin resistance alone
- PCOS-related insulin resistance
Those may be scientifically relevant search areas without being approved indications.
What About “Food Noise”?
This term isn’t a formal medical diagnosis, but people use it to describe:
persistent thoughts about food + cravings + mental preoccupation with eating.
GLP-1-based therapies commonly reduce appetite and food-seeking behavior in many patients.
Retatrutide’s GLP-1 and GIP activity makes appetite regulation a legitimate area of interest.
But clinical trials generally measure things such as:
body weight + appetite scores + metabolic outcomes
rather than establishing “food noise elimination” as a formal indication.
Still, it belongs in the search keywords because that’s exactly how many people describe the experience they’re researching.
What About Belly Fat & Visceral Fat?
Large overall weight reductions usually include losses in both:
subcutaneous fat + visceral fat.
Retatrutide has also produced substantial reductions in waist circumference.
In TRIUMPH-1, the 12-mg group reduced average waist circumference by:
24.1 cm — about 9.5 inches.
Placebo participants lost about 3.6 cm.
That supports genuine effects on central adiposity.
But retatrutide does not specifically seek out and “melt belly fat.”
Body-fat distribution changes as part of overall weight loss.
What About Cholesterol & Triglycerides?
Phase 3 research has shown improvements in several cardiometabolic markers.
TRIUMPH-1 reported improvements involving:
- Triglycerides
- Non-HDL cholesterol
- Blood pressure
- Waist circumference
- hsCRP
TRIUMPH-3, which studied adults with severe obesity and established cardiovascular disease, reported that the highest dose reduced average:
Triglycerides → 37.0%
Non-HDL cholesterol → 16.5%
Systolic blood pressure → 9.3 mmHg
hsCRP → 51.2%.
Those are encouraging risk-factor changes.
But risk-factor improvement is not identical to proving fewer heart attacks or strokes.
Does Retatrutide Prevent Heart Attacks?
We don’t know yet.
TRIUMPH-3 enrolled people with established cardiovascular disease and collected cardiovascular-event data.
But the trial was not powered to establish a definitive cardiovascular benefit.
The confidence intervals around major cardiovascular-event estimates were wide and included both potential benefit and potential harm.
A much larger dedicated trial called:
TRIUMPH-Outcomes
is currently studying cardiovascular and kidney outcomes.
Until those results are available, retatrutide should not be described as proven to prevent heart attacks, strokes, or cardiovascular death.
What About Fatty Liver?
Retatrutide is also being studied in:
metabolic dysfunction-associated steatotic liver disease — MASLD
because obesity, insulin resistance and liver fat are closely connected.
Earlier research has suggested powerful reductions in liver fat with retatrutide, and Lilly’s Phase 3 program includes MASLD development.
This makes:
fatty liver + liver fat + MASLD
legitimate research categories.
But approval for liver disease has not occurred.
What About Sleep Apnea?
This is now a legitimate Phase 3 area.
TRIUMPH-1 included a subgroup with moderate-to-severe obstructive sleep apnea.
Lilly reported that retatrutide reduced sleep apnea severity by as much as:
36.1 breathing events per hour
or approximately:
60.6%.
Much of that benefit may relate to substantial weight loss, since obesity is a major driver of obstructive sleep apnea.
But these results show that retatrutide’s development is increasingly focused not just on weight itself, but on obesity-related complications.
What About Knee Arthritis?
This is one of the most interesting Phase 3 findings.
TRIUMPH-4 studied adults with obesity or overweight and knee osteoarthritis.
At 68 weeks, participants receiving 12 mg lost an average of:
28.7% of body weight
while knee-pain scores fell by an average of:
75.8%.
More than one in eight retatrutide-treated participants reportedly had no knee pain at the end of the trial.
That’s impressive.
But we need to be careful about what caused the improvement.
Major weight loss reduces mechanical stress on weight-bearing joints.
Improved inflammation and metabolic health could potentially contribute as well.
That does not establish retatrutide as a direct cartilage-regenerating or arthritis-healing drug.
Does Retatrutide Heal Joints?
No evidence establishes that.
The osteoarthritis results demonstrate:
major weight loss + major improvement in pain and physical function.
They do not demonstrate:
cartilage regeneration + reversal of osteoarthritis + repair of damaged joints.
That’s an important distinction.
What About Inflammation?
Obesity itself is associated with chronic low-grade inflammation.
In TRIUMPH-3, hsCRP—a commonly measured inflammatory marker—fell substantially.
That makes inflammation and metabolic inflammation legitimate research topics.
But retatrutide is not an anti-inflammatory drug in the same sense as a corticosteroid, NSAID, or targeted immune therapy.
Does Retatrutide Preserve Muscle?
This is an important question with any powerful weight-loss therapy.
When people lose a large amount of body weight, they usually lose:
fat mass + some lean mass.
Researchers are studying body-composition effects across the incretin class.
There’s currently no basis for saying retatrutide specifically:
builds muscle
or:
completely prevents muscle loss.
Adequate protein intake, resistance exercise, health status, age, and the speed and magnitude of weight loss all matter.
What About Hair Loss?
Hair loss can occur after substantial or rapid weight loss from many causes, including:
major calorie reduction + physiological stress + nutrient deficiencies + rapid body-weight change.
That doesn’t necessarily mean retatrutide directly damages hair follicles.
Hair loss hasn’t emerged as the defining adverse effect in the retatrutide Phase 3 results, but because weight loss can be so large, hair shedding during rapid weight loss is a relevant topic for readers.
What Are the Main Side Effects?
The most common adverse events in TRIUMPH-1 were gastrointestinal.
At 12 mg, Lilly reported:
Nausea → 42.4%
Diarrhea → 32.0%
Constipation → 26.1%
Vomiting → 25.3%.
These were generally similar to adverse effects seen with other incretin medications.
Treatment discontinuation due to adverse events increased with dose:
4 mg → 4.1%
9 mg → 6.9%
12 mg → 11.3%
compared with:
4.9% placebo.
So the higher efficacy came with more tolerability problems.
What Is Dysesthesia?
This was a somewhat unusual finding in Phase 3.
Dysesthesia refers to abnormal or unpleasant skin sensations, which may be described as:
- Tingling
- Burning
- Prickling
- Altered skin sensitivity
- Uncomfortable sensation when touched
In TRIUMPH-1, dysesthesia occurred in:
5.1% at 4 mg
12.3% at 9 mg
12.5% at 12 mg
versus:
0.9% with placebo.
Most cases were reported as mild to moderate and many resolved during continued treatment.
That’s an interesting safety signal to watch as more data accumulate.
What About Heart Rate?
The Phase 2 study found dose-dependent increases in heart rate, which peaked around 24 weeks and later declined.
This may relate partly to glucagon receptor activation.
Because retatrutide has a mechanism that differs somewhat from semaglutide and tirzepatide, researchers need long-term cardiovascular data before assuming its overall cardiovascular effects.
What About Gallbladder Problems & Pancreatitis?
Drugs acting through GLP-1 pathways are monitored for issues involving:
- Gallbladder disease
- Pancreatitis
- Severe gastrointestinal effects
- Dehydration
- Kidney problems related to fluid loss
Retatrutide’s final prescribing information does not yet exist because it has not been approved.
So we should not simply copy the warning label from semaglutide or tirzepatide and pretend it is retatrutide’s official label.
These remain important safety areas being evaluated across clinical development.
What About Thyroid Cancer?
Same problem.
Approved GLP-1-based medications such as semaglutide and tirzepatide carry boxed warnings relating to thyroid C-cell tumors observed in rodents.
Retatrutide is still investigational and does not yet have a final FDA-approved label.
It would therefore be premature to present another drug’s exact contraindications as established retatrutide labeling.
This is something that will become much clearer if and when FDA reviews and approves the drug.
Retatrutide vs. Tirzepatide
Tirzepatide
Targets:
GIP + GLP-1
FDA approved.
Marketed as:
Mounjaro for type 2 diabetes
and:
Zepbound for obesity and other approved indications.
Retatrutide
Targets:
GIP + GLP-1 + glucagon
Still investigational.
Phase 3 results have shown average weight loss approaching 30%.
No FDA approval yet.
No proven head-to-head superiority yet.
Retatrutide vs. Semaglutide
Semaglutide
Targets:
GLP-1
FDA approved.
Retatrutide
Targets:
GLP-1 + GIP + glucagon
Still investigational.
Again, the triple mechanism is scientifically exciting, but:
more receptors does not automatically mean better medication.
Efficacy, safety, tolerability, long-term outcomes and real-world use all matter.
Is Retatrutide the “Triple G”?
You’ll sometimes see retatrutide referred to online as:
Triple G
because of:
GIP + GLP-1 + glucagon.
It’s an informal nickname, not the scientific or pharmaceutical name.
It’s useful as a search keyword because people absolutely use it.
Is Retatrutide FDA Approved?
No.
As of September 2026, retatrutide has not been approved by FDA or any other regulatory agency. Lilly states that the legitimate drug is available only through its sponsored clinical trials.
Lilly plans to submit a Biologics License Application in Q1 2027.
That means bottles and vials currently sold online as:
retatrutide
are not FDA-approved Lilly retatrutide products.
Can Retatrutide Be Compounded?
This deserves a very clear answer.
No—not legally under current federal compounding law.
FDA explicitly states that retatrutide cannot be used in compounding.
FDA explains that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition. The agency has also warned companies marketing unapproved retatrutide.
That’s stronger than merely saying:
“compounded retatrutide isn’t FDA approved.”
FDA’s current position is:
Retatrutide cannot legally be used in compounding.
What About Online “Research Retatrutide”?
This distinction is particularly important for our site.
Lilly has warned that products claiming to contain retatrutide outside its clinical trials may contain:
- Unknown ingredients
- Harmful contaminants
- Impurities
- Too much active ingredient
- Too little active ingredient
- An entirely different ingredient
So there is a massive difference between:
Lilly’s investigational retatrutide used in controlled clinical trials
and:
a gray-market vial labeled “retatrutide.”
The Phase 3 trial results validate the investigational Lilly drug.
They do not validate every online product using its name.
Evidence Snapshot
Laboratory/Mechanistic Research: Yes
Animal Research: Yes
Human Phase 1 Research: Yes
Human Phase 2 Research: Yes
Large Phase 3 Trials: Yes
Obesity Evidence: Strong Phase 3 evidence
Type 2 Diabetes Evidence: Phase 3 evidence
Knee Osteoarthritis Outcomes: Phase 3 evidence for pain/function improvement in people with obesity
Sleep Apnea Outcomes: Phase 3 evidence
Cardiometabolic Risk Markers: Encouraging Phase 3 evidence
Definitive Cardiovascular Outcome Benefit: Not established yet
FDA Approved: No
Legal Compounded Retatrutide: No under current federal law
Overall Evidence: Extremely strong evidence for major weight reduction, with Phase 3 development now covering several obesity-related diseases; regulatory review has not yet occurred.
What Do We Know?
Retatrutide is no longer one of those compounds where everything exciting comes from mice.
It now has substantial human clinical evidence.
The Phase 2 trial showed up to 24.2% average weight loss at 48 weeks.
Phase 3 TRIUMPH-1 then reported 28.3% average loss at 80 weeks, reaching 30.3% in one 104-week extension population.
Phase 3 trials have also demonstrated meaningful effects involving:
type 2 diabetes + knee osteoarthritis pain + obstructive sleep apnea + cardiometabolic risk factors.
So the evidence for retatrutide’s biological and weight-loss activity is no longer speculative.
What Don’t We Know?
We still don’t know whether retatrutide will:
- Receive FDA approval
- Receive approval at every studied dose
- Receive all of the indications currently under study
- Prove superior to tirzepatide head-to-head
- Reduce cardiovascular death
- Reduce heart attacks or stroke
- Improve kidney outcomes long term
- Provide durable benefits over many years
- Maintain the same safety profile in millions of real-world patients
- Have rare adverse effects not detectable during trials
- Preserve muscle better than existing therapies
- Produce permanent weight loss after discontinuation
- Be appropriate for people without obesity or metabolic disease
- Have the same risk/benefit profile as semaglutide or tirzepatide
And we absolutely cannot assume an online research product has the same:
purity + identity + concentration + stability
as Lilly’s clinical-trial medication.
Research & Regulatory Status
As of September 2026:
Retatrutide remains investigational.
It is not FDA approved.
Lilly’s Phase 3 program has produced positive results across obesity, type 2 diabetes, cardiovascular-disease populations, osteoarthritis and sleep apnea. Additional outcomes research is continuing.
Lilly says it plans its U.S. regulatory submission for Q1 2027.
FDA also explicitly states that retatrutide currently cannot be used in compounding under federal law.
Your Pep Resource Takeaway
Retatrutide is one of the rare research peptides where the hype is attached to genuinely remarkable clinical-trial results.
This isn’t:
“someone injected it into mice and now TikTok calls it a miracle.”
We now have large Phase 3 trials.
In adults with obesity without diabetes:
28.3% average weight loss at 80 weeks.
In a subgroup followed longer:
roughly 30% average loss at 104 weeks.
And the program has shown improvements in conditions closely tied to obesity—including type 2 diabetes, knee osteoarthritis pain and obstructive sleep apnea.
So calling retatrutide merely “experimental with no human evidence” would now be completely outdated.
But the other extreme is equally wrong.
It is not currently an FDA-approved medication.
It has not been proven superior to tirzepatide in a direct head-to-head trial.
And the impressive Lilly clinical-trial evidence does not validate gray-market vials being sold online under the retatrutide name.
The accurate 2026 description is:
Retatrutide is a highly advanced investigational triple agonist with exceptionally strong Phase 3 weight-loss results—but it is still awaiting regulatory review.
Research Areas / Search Keywords
Retatrutide, reta, retatrutide peptide, LY3437943, triple agonist, triple receptor agonist, triple hormone agonist, Triple G, triple G peptide, GIP GLP-1 glucagon, GLP-1, GLP1, GIP, glucagon, glucagon receptor, GLP-1 receptor agonist, GIP receptor agonist, glucagon receptor agonist, incretin, incretin therapy, incretin peptide, obesity, obesity research, obesity medication research, weight loss, weight-loss peptide, weight loss injection, weight management, major weight loss, extreme weight loss research, body weight, body composition, body fat, fat loss, belly fat, abdominal fat, visceral fat, stubborn fat, waist circumference, appetite, appetite suppression, reduced appetite, hunger, hunger control, cravings, food cravings, food noise, food thoughts, satiety, fullness, portion control, metabolic health, metabolism, energy expenditure, thermogenesis, fat metabolism, lipid metabolism, insulin resistance, insulin sensitivity, glucose metabolism, blood sugar, A1C, HbA1c, diabetes, type 2 diabetes, T2D, prediabetes research, metabolic syndrome, PCOS research, obesity and PCOS, fatty liver, liver fat, fatty liver disease, NAFLD, MASLD, metabolic dysfunction-associated steatotic liver disease, cholesterol, triglycerides, non-HDL cholesterol, cardiovascular health, heart disease research, cardiovascular disease, blood pressure, hypertension research, hsCRP, inflammation, metabolic inflammation, chronic inflammation, cardiovascular outcomes, heart attack research, stroke research, kidney outcomes, CKD research, chronic kidney disease, sleep apnea, obstructive sleep apnea, OSA, snoring research, obesity sleep apnea, osteoarthritis, knee osteoarthritis, knee arthritis, knee pain, joint pain, arthritis and weight loss, WOMAC, physical function, mobility, chronic low back pain research, muscle loss, lean mass, muscle preservation, sarcopenia research, rapid weight loss, hair loss, hair shedding, nausea, diarrhea, constipation, vomiting, gastrointestinal side effects, GI side effects, dysesthesia, tingling skin, burning skin sensation, skin sensitivity, heart rate, increased heart rate, gallbladder research, pancreatitis research, retatrutide side effects, retatrutide safety, retatrutide clinical trials, retatrutide Phase 2, retatrutide Phase 3, TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4, TRIUMPH Outcomes, TRANSCEND T2D, retatrutide 2026, retatrutide FDA approval, when will retatrutide be approved, retatrutide FDA 2027, compounded retatrutide, research retatrutide, gray market retatrutide, retatrutide vs tirzepatide, retatrutide vs Mounjaro, retatrutide vs Zepbound, retatrutide vs semaglutide, retatrutide vs Ozempic, retatrutide vs Wegovy, tirzepatide, Mounjaro, Zepbound, semaglutide, Ozempic, Wegovy, GLP-1 medications, next generation GLP-1, obesity peptides.
Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, weight-loss treatment, compounding, or purchasing recommendations. Retatrutide remains investigational as of September 2026 and has not been approved by FDA or any other regulatory agency. FDA currently states that retatrutide cannot be used in compounding under federal law. Phase 2 and Phase 3 results discussed here refer to Eli Lilly’s investigational drug used in controlled clinical trials and should not be assumed to apply to products sold online under the retatrutide name.